The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.

PHILADELPHIA, PA—Zilebesiran (Alnylam), an investigational therapeutic agent that interferes with messenger RNA to stop the production of angiotensinogen (AGT), lowers systolic blood pressure levels ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...

SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

In such individuals, known to be at increased risk of atherosclerotic cardiovascular disease (ASCVD), plozasiran at various doses conferred significantly larger reductions over placebo in fasting ...